On Thursday, Akebia Therapeutics Inc. (NASDAQ: AKBA) announced topline results from the Phase 3 PRO2TECT studies evaluating the safety and efficacy of vadadustat in chronic kidney disease (CKD). Shares were crushed afterward. This is…
Auris Medical has reported topline data from its Phase 2 Travers trial with intranasal betahistine in vertigo.
Conn’s reported mixed fiscal second-quarter financial results and offered no guidance before the markets opened on Thursday.
Cloudera top consensus earnings expectations, but the topline guidance disappointed.
Cybersecurity firm CrowdStrike posted second-quarter earnings per share (EPS) of $0.03 and $199.0 million in revenue. Consensus estimates had called for a net loss of $0.01 per share and $188.54 million in revenue.
JPMorgan has reiterated its Overweight rating on Peloton and raised the price target to a street-high $105.
NBA Hall of Fame inductee Michael Jordan will be joining DraftKings as a special advisor to the board of directors.
Guess reported better than expected fiscal second-quarter financial results before the markets opened on Wednesday.
Jounce Therapeutics Inc. (NASDAQ: JNCE) made a massive gain on Tuesday after the company announced a licensing agreement with Gilead Sciences Inc. (NASDAQ: GILD). This deal is for the discovery and development of novel…
24/7 Wall St. has included some highlights from the Zoom Video Communications earnings report, as well as what analysts are saying about the stock after the fact.
Like many retailers, J.Jill has been brutalized by the COVID-19 crisis and has drawn down on its credit facilities to stay afloat. An update of its financial situation to investors suggests that things may…
Plus Therapeutics shares rallied on Tuesday after an FDA update on its treatment of patients with recurrent glioblastoma.
Eastman Kodak shares jumped on Tuesday after it was disclosed that an investment firm took a sizable stake in the company.
Zoom Communications reported earnings per share (EPS) of $0.92 and $663.5 million in revenue after markets closed Monday. Consensus estimates had called for $0.45 in EPS and $500.45 million in revenue.
The prize for Nestle in its acquisition of Aimmune Therapeutics is Palforzia, the world’s first treatment for a food allergy.
Akcea Therapeutics stock jumped on Monday after it was announced that Ionis Pharmaceuticals would be acquiring all of its outstanding shares.
24/7 Wall St. has previewed some of the key companies expected to report results this week, including Broadcom, Macy's and Zoom Video.
HP shares got a boost after it released fiscal third-quarter financial results that were lower year over year but better than expected.
Ulta Beauty posted much better bottom-line results than expected, sending shares sharply higher Friday morning.
Dell Technologies reported better than expected second-quarter results, sending shares to a new 52-week high.
